Protocol | Published:

The cellular thermal shift assay for evaluating drug target interactions in cells

Nature Protocols volume 9, pages 21002122 (2014) | Download Citation

Abstract

Thermal shift assays are used to study thermal stabilization of proteins upon ligand binding. Such assays have been used extensively on purified proteins in the drug discovery industry and in academia to detect interactions. Recently, we published a proof-of-principle study describing the implementation of thermal shift assays in a cellular format, which we call the cellular thermal shift assay (CETSA). The method allows studies of target engagement of drug candidates in a cellular context, herein exemplified with experimental data on the human kinases p38α and ERK1/2. The assay involves treatment of cells with a compound of interest, heating to denature and precipitate proteins, cell lysis, and the separation of cell debris and aggregates from the soluble protein fraction. Whereas unbound proteins denature and precipitate at elevated temperatures, ligand-bound proteins remain in solution. We describe two procedures for detecting the stabilized protein in the soluble fraction of the samples. One approach involves sample workup and detection using quantitative western blotting, whereas the second is performed directly in solution and relies on the induced proximity of two target-directed antibodies upon binding to soluble protein. The latter protocol has been optimized to allow an increased throughput, as potential applications require large numbers of samples. Both approaches can be completed in a day.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    et al. Monitoring drug target engagement in cells and tissues using the cellular thermal shift assay. Science 341, 84–87 (2013).

  2. 2.

    & Study of strong to ultratight protein interactions using differential scanning calorimetry. Biochemistry 29, 6927–6940 (1990).

  3. 3.

    Statistical thermodynamics of nucleic acid melting transitions with coupled binding equilibria. Biopolymers 10, 2147–2160 (1971).

  4. 4.

    Macromolecular binding. Biopolymers 14, 999–1018 (1975).

  5. 5.

    , , & Thermodynamic stability of carbonic anhydrase: measurements of binding affinity and stoichiometry using ThermoFluor. Biochemistry 44, 5258–5266 (2005).

  6. 6.

    , , , & ThermoFluor-based high-throughput stability optimization of proteins for structural studies. Anal. Biochem. 357, 289–298 (2006).

  7. 7.

    , & The use of differential scanning fluorimetry to detect ligand interactions that promote protein stability. Nat. Protoc. 2, 2212–2221 (2007).

  8. 8.

    et al. High-density miniaturized thermal shift assays as a general strategy for drug discovery. J. Biomol. Screen. 6, 429–440 (2001).

  9. 9.

    et al. Screening for ligands using a generic and high-throughput light-scattering-based assay. J. Biomol. Screen. 11, 940–948 (2006).

  10. 10.

    et al. A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. Proc. Natl. Acad. Sci. USA 104, 20523–20528 (2007).

  11. 11.

    et al. Chemical screening methods to identify ligands that promote protein stability, protein crystallization, and structure determination. Proc. Natl. Acad. Sci. USA 103, 15835–15840 (2006).

  12. 12.

    et al. Systematic identification of genomic markers of drug sensitivity in cancer cells. Nature 483, 570–575 (2012).

  13. 13.

    et al. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 483, 603–607 (2012).

  14. 14.

    & A detergent-based assay for the detection of promiscuous inhibitors. Nat. Protoc. 1, 550–553 (2006).

  15. 15.

    & Designing screens: how to make your hits a hit. Nat. Rev. Drug Disc. 2, 259–266 (2003).

  16. 16.

    Methods for determining ligand binding to a target protein using a thermal shift assay. UK patent no. GB2490404 (2012).

  17. 17.

    et al. Proximity ligation assays: a recent addition to the proteomics toolbox. Exp. Rev. Proteom. 7, 401–409 (2010).

  18. 18.

    & Screening for soluble expression of recombinant proteins in a 96-well format. Anal. Biochem. 297, 79–85 (2001).

  19. 19.

    et al. Engineering protein thermostability using a generic activity-independent biophysical screen inside the cell. Nat. Commun. 4, 2901 (2013).

  20. 20.

    et al. HiRIEF LC-MS enables deep proteome coverage and unbiased proteogenomics. Nat. Methods 11, 59–62 (2014).

  21. 21.

    et al. The use of AlphaScreen technology in HTS: current status. Curr. Chem. Genomics 1, 2–10 (2008).

  22. 22.

    , , & Homogeneous time resolved fluorescence resonance energy transfer using rare earth cryptates as a tool for probing molecular interactions in biology. Spectrochim. Acta. A Mol. Biomol. Spectrosc. 57, 2197–2211 (2001).

  23. 23.

    , & Development of cell-based assays for cytokine receptor signaling, using an AlphaScreen SureFire assay format. Anal. Biochem. 403, 94–9101 (2010).

  24. 24.

    et al. Determination of complementary antibody pairs using protein A capture with the AlphaScreen assay format. Anal. Biochem. 408, 321–327 (2011).

  25. 25.

    , & Drug-target residence time and its implications for lead optimization. Nat. Rev. Drug Disc. 5, 730–739 (2006).

  26. 26.

    et al. Influence of transition rates and scan rate on kinetic simulations of differential scanning calorimetry profiles of reversible and irreversible protein denaturation. Biochemistry 31, 12706–12712 (1992).

  27. 27.

    et al. Structural and biophysical characterization of the cytoplasmic domains of human BAP29 and BAP31. PLoS ONE 8, e71111 (2013).

  28. 28.

    et al. Role for p38 mitogen-activated protein kinase in platelet aggregation caused by collagen or a thromboxane analogue. J. Biol. Chem. 271, 6586–6589 (1996).

  29. 29.

    , & p38 MAP kinase inhibitors: many are made, but few are chosen. Curr. Opin. Drug Disc. Dev. 8, 421–430 (2005).

  30. 30.

    et al. Structure-guided design of potent and selective pyrimidylpyrrole inhibitors of extracellular signal-regulated kinase (ERK) using conformational control. J. Med. Chem. 52, 6362–6368 (2009).

  31. 31.

    , & A simple statistical parameter for use in evaluation and validation of high-throughput screening assays. J. Biomol. Screen. 4, 67–73 (1999).

  32. 32.

    , , & The binding of staphylococcal protein A by the sera of different animal species. J. Immunol. 128, 2300–2305 (1982).

Download references

Acknowledgements

D.M.M., R.J., M.I. and P.N. acknowledge Karolinska Institutet (Distinguished Professor Award), the Swedish Research Council (Vetenskapsrådet) and the Swedish Cancer Society (Cancerfonden). T.L., H. Almqvist and H. Axelsson acknowledge Karolinska Institutet and the Swedish Research Council, which funds Chemical Biology Consortium Sweden, a national infrastructure for research in the field of chemical Biology, as well as Biovitrum for a generous donation of instruments and compound libraries when Chemical Biology Consortium Sweden was inaugurated. We are also grateful to C. Zaniol at PerkinElmer for great support in the development of the AlphaScreen assays.

Author information

Affiliations

  1. Department of Medical Biochemistry and Biophysics, Division of Biophysics, Karolinska Institutet, Stockholm, Sweden.

    • Rozbeh Jafari
    • , Marina Ignatushchenko
    • , Pär Nordlund
    •  & Daniel Martinez Molina
  2. Chemical Biology Consortium Sweden, Science for Life Laboratory Stockholm, Division of Translational Medicine and Chemical Biology, Department of Medical Biochemistry and Biophysics, Karolinska Institutet, Solna, Sweden.

    • Helena Almqvist
    • , Hanna Axelsson
    •  & Thomas Lundbäck

Authors

  1. Search for Rozbeh Jafari in:

  2. Search for Helena Almqvist in:

  3. Search for Hanna Axelsson in:

  4. Search for Marina Ignatushchenko in:

  5. Search for Thomas Lundbäck in:

  6. Search for Pär Nordlund in:

  7. Search for Daniel Martinez Molina in:

Contributions

R.J., H. Axelsson, H. Almqvist, M.I., T.L., P.N. and D.M.M. conceived the study; R.J., H. Axelsson, H. Almqvist, T.L. and D.M.M. designed the experiments and the high-throughput formatting of the CETSA procedure; western blot and the AlphaScreen experiments were conducted by R.J., D.M.M., H. Axelsson, H. Almqvist and T.L.; and the manuscript was prepared by R.J., H. Axelsson, H. Almqvist, M.I., T.L., P.N. and D.M.M.

Competing interests

D.M.M. and P.N. are the founders of Pelago Bioscience AB. The remaining authors declare no competing financial interests.

Corresponding authors

Correspondence to Thomas Lundbäck or Pär Nordlund or Daniel Martinez Molina.

Integrated supplementary information

Supplementary information

PDF files

  1. 1.

    Supplementary Figure 1

    Cellular integrity after heating.

  2. 2.

    Supplementary Figure 2

    Chemical structures.

  3. 3.

    Supplementary Figure 3

    Negative control compound on p38α.

  4. 4.

    Supplementary Figure 4

    ITDRFCETSA confirmation of CBK derived hit compounds.

  5. 5.

    Supplementary Data

    Positive control compound on ERK1/2.

About this article

Publication history

Published

DOI

https://doi.org/10.1038/nprot.2014.138

Further reading

Comments

By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.